T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 399.45 INR -0.61%
Market Cap: 1.2T INR
Have any thoughts about
Torrent Pharmaceuticals Ltd?
Write Note

Torrent Pharmaceuticals Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torrent Pharmaceuticals Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Revenue
â‚ą112.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
9%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Revenue
â‚ą300.8B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Revenue
â‚ą265.1B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Revenue
â‚ą503.1B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
8%
Lupin Ltd
NSE:LUPIN
Revenue
â‚ą214.3B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
5%
M
Mankind Pharma Ltd
NSE:MANKIND
Revenue
â‚ą103.3B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling realm of Indian pharmaceuticals, Torrent Pharmaceuticals Ltd. has carved out a notable niche, emerging from the industrious land of Gujarat. Founded in 1959, this company has transformed from a modest player to a major force in the industry, traversing the complexities of pharmaceutical manufacturing and global distribution. At its core, Torrent Pharmaceuticals is driven by a commitment to healthcare innovation and therapeutic excellence. The company systematically engages in developing, manufacturing, and marketing a wide array of generic pharmaceutical products primarily targeting cardiovascular, central nervous system, gastro-intestinal, anti-infective, and anti-diabetic therapeutic categories. This diverse product portfolio positions Torrent not just as a provider of remedies but as a critical player in improving health outcomes across numerous demographics and geographies. Torrent Pharmaceuticals operates on a robust business model that effectively integrates research, development, and widespread distribution to generate revenue. The company channels significant resources into its R&D capabilities, perpetually expanding its pipeline to introduce more effective and affordable medications. This ongoing innovation supports their competitive edge while fortifying their catalog of offerings. Additionally, Torrent's strategic alliances and acquisitions—most notably, the key acquisition of Elder Pharmaceuticals' branded domestic formulations business in India—have further catapulted its market presence both domestically and internationally. By leveraging its extensive marketing network and manufacturing capabilities compliant with international standards, Torrent not only bankrolls its growth through product sales but also ensures global reach, cementing its role as a pivotal component of the healthcare landscape.

TORNTPHARM Intrinsic Value
1 989.4 INR
Overvaluation 41%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's Revenue?
Revenue
112.2B INR

Based on the financial report for Sep 30, 2024, Torrent Pharmaceuticals Ltd's Revenue amounts to 112.2B INR.

What is Torrent Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 10Y
9%

Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for Torrent Pharmaceuticals Ltd have been 11% over the past three years , 7% over the past five years , and 9% over the past ten years .

Back to Top